C71 Robot-assisted radical cystectomy with intracorporeal ileal neobladder – initial experience

Boc, A.; Pop, C.D.; Crişan, Nicolae; Mihály, Zsuzsanna; Coman, Ioan

doi:10.1016/s1569-9056(13)61919-3

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Continence figures are relevant to those patients undergoing orthotopic neobladder at the same time as male NS RARC and satisfactory continence is defined in the studies to be dry enough to maintain with a maximum of one pad per day. In this review, 85.06% day time continence rate (range 54.5%-100%) and 72.48% night time continence rate (range 46.7%-88%) were noted overall in patients whose NVBs were preserved [13,17,18,[20][21][22]26,[29][30][31][33][34][35][36][37][38][39][40] . This is in contrast to the results of some studies, for example, Tyritzis et al [38] , who noted no significant difference in continence rates between their NS and non-NS groups of patients with 88.2% and 88.9% respectively for day time continence rates at 12 months.…”

Section: Discussionmentioning

confidence: 95%

Functional and oncological outcomes with male nerve sparing robotic assisted radical cystectomy

Thinagaran¹,

Maqboul²,

Dovey³

et al. 2021

MIS

View full text Add to dashboard Cite

Aim:In keeping with the ethos of surgical oncology, male nerve sparing (NS) robotic assisted radical cystectomy (RARC) aims to maximise functional outcomes without sacrificing oncological outcomes. This review details the surgical technique of male NS RARC as well as discussing strategies that may be employed in tandem with surgery to improve post-operative recovery and longer-term quality of life.Methods: An OVID/EMBASE database search was done with key words of robotic, cystectomy, male and nerve sparing. Publications with no description of post-operative functional outcome were excluded. A total number of 25 relevant publications were selected investigating male NS RARC, assessing functional outcomes along with other surgical standard indicators.Results: Most series contained small numbers of patients with largely retrospective data and the associated bias of selection. Mean follow up of 27.06 months (range 2.8-58 months) was noted overall. Study design, technique, definitions and measurements of continence and erectile function are heterogeneous across series. With a mean follow up of 27.06 months (range 2.8-58 months), a post-operative satisfactory erectile function of 54.32% (range 9%-100%) and satisfactory day time continence of 90% (range 54.5%-100%) and night time continence of 80.55% (range 46.7%-88%) was found with a mean positive surgical margin rate of only 1.8% (range 0%-6.4%). Conclusion:Male NS RARC for appropriately selected patients will offer good functional outcomes. Results from the series reviewed suggest the technique is both feasible and safe, without compromising longer term oncological results.

show abstract